Diabetes Australia welcomes the Federal Authorities’s determination to ban replicas of Ozempic and different weight reduction medicines following security considerations.
Pharmacies compounding their very own variations of those medicines have been ordered to cease manufacturing from October 1, 2024.
The brand new laws will take away glucagon-like peptide-1 receptor agonists (GLP-1RAs), lots of which declare to be replicas of Ozempic or Mounjaro, from the pharmacy compounding exemption.
Diabetes Australia understands the numerous considerations of Australians dwelling with sort 2 diabetes in regards to the ongoing world scarcity of Ozempic specifically, and can proceed to advocate for prioritised entry for individuals dwelling with diabetes.
Nonetheless, on the subject of compounded variations, the well being and wellbeing of the neighborhood should be an important consideration.
The compounded GLP-1RA merchandise the federal government has banned haven’t been evaluated by the TGA for security, high quality and efficacy. When a medication is compounded, it could actually have a distinct power and completely different components from comparable medicines permitted by the TGA.
Diabetes Australia has advocated for the Therapeutic Items Administration (TGA) to analyze the shortages of numerous diabetes-related medicines and merchandise lately and redouble efforts to make sure Australians could be assured that provide chains are enough to satisfy their wants.
Extra details about the security of those merchandise could be discovered on the TGA web site.
